Covered recipient · General Payments record
SHERI M GONZALES
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$1,576.47
- Reported across 59 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $463.82 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $160.25 | 4 |
| Paratek Pharmaceuticals, Inc. | $125.00 | 1 |
| Lilly USA, LLC | $61.34 | 4 |
| PFIZER INC. | $38.85 | 2 |
| Sumitomo Pharma America, Inc. | $19.38 | 1 |
| Otsuka America Pharmaceutical, Inc. | $16.66 | 1 |
| Acerta Pharma LLC | $14.67 | 1 |
| Novo Nordisk AS | $13.93 | 1 |
| ABBVIE INC. | $13.74 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.74 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107234224 | CMS |
| Amgen Inc. | $14.25 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117263011 | CMS |
| Amgen Inc. | $11.49 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117263013 | CMS |
| Amgen Inc. | $125.00 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117263015 | CMS |
| Amgen Inc. | $9.51 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117564588 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.67 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104586572 | CMS |
| Lilly USA, LLC | $13.32 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135940232 | CMS |
| Lilly USA, LLC | $14.59 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135949484 | CMS |
| Lilly USA, LLC | $16.83 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135889490 | CMS |
| Lilly USA, LLC | $16.60 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135865600 | CMS |
| Novo Nordisk Inc | $13.93 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100336627 | CMS |
| Otsuka America Pharmaceutical, Inc. | $16.66 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119081430 | CMS |
| Paratek Pharmaceuticals, Inc. | $125.00 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1113928230 | CMS |
| PFIZER INC. | $17.09 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131796066 | CMS |
| PFIZER INC. | $21.76 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132110575 | CMS |
| Sumitomo Pharma America, Inc. | $19.38 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148963216 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.